Skip to content

Welcome to Discover Pharma! Today is : November 10, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Discovery & Development

  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    AC Immune doses first participant in Phase 1 trial of NLRP3 inhibitor ACI-19764

    AC Immune has initiated a Phase 1 trial of its [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Link Biologics appoints Niall Martin to board as TSG-6 pipeline advances towards clinic

    Link Biologics has appointed Niall Martin to its board as [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    etherna intratumoral mRNA/LNP platform advances toward IND studies in non-melanoma skin cancer

    etherna, a biotech company specialising in mRNA and lipid nanoparticle [...]

    May 5, 2026
  • Digital & Data,Drug Discovery & Development

    Promise Bio launches grant to support translational epiproteomics in biotech research

    Promise Bio has launched the Frontier Epiproteomic Innovation Grant, providing [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development

    MaxCyte launches 96-well electroporation platform for cell therapy discovery

    MaxCyte, Inc. has launched ExPERT DTx, a 96-well electroporation platform [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Patients with Crohn’s disease maintain steroid-free remission for three years with Lilly’s Omvoh (mirikizumab)

    Long-term VIVID-2 data show more than 90% of patients with [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    International Brain Health Conference 2026 to focus on early intervention before dementia

    The inaugural International Brain Health Conference 2026 in Edinburgh will [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Hansa Biopharma’s BLA for imlifidase accepted by FDA

    Hansa Biopharma’s Biologics License Application (BLA) for imlifidase has been [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Lario receives $2.4M from MJFF and Wellcome to expand neuronal calcium channel research in CNS disorders

    Lario Therapeutics awarded $2.4M by The Michael J. Fox Foundation [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain

    Lonza expands bioconjugate capabilities at Oss site to support ADC development

    Lonza expands its Advanced Synthesis capabilities at Oss, integrating ADC [...]

    May 5, 2026
Previous252627Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Isomab data support safety of angiogenic approaches in coronary artery disease
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • FDA approves Tivicay PD for children with HIV weighing at least 2kg
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Tezspire meets Phase 3 endpoints in eosinophilic esophagitis
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top